Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma

18 Mar 2017

Abstract excerpt

// Chiaki Tsuge Ishida 1 , Elena Bianchetti 1 , Chang Shu 1 , Marc-Eric Halatsch 2 , M. Andrew Westhoff 3 , Georg Karpel-Massler 2 and Markus D. Siegelin 1 1 Department of Pathology & Cell Biology, Columbia University Medical Center, New York, New York, USA 2 Department of Neurosurgery, Ulm University Medical Center, Ulm, Germany 3 Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to RNA Interference and Gene Delivery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28418907
DOI: 10.18632/oncotarget.16365

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant gliomaPMID 28418907Read ↗

BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant gliomaSemantic proximity Read ↗

Bak and Mcl-1 are essential for Temozolomide induced cell death in human gliomaSemantic proximity Read ↗

How to train glioma cells to die: molecular challenges in cell deathSemantic proximity Read ↗

A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastomaSemantic proximity Read ↗

BH3 Mimetics in Hematologic MalignanciesSemantic proximity Read ↗

BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the ClinicSemantic proximity Read ↗

Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulationSemantic proximity Read ↗

Bromodomain and Extraterminal Domain (BET) Protein Inhibition Hinders Glioblastoma Progression by Inducing Autophagy-Dependent DifferentiationSemantic proximity Read ↗

The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cellsSemantic proximity Read ↗

Apoptotic Signaling Pathways in Glioblastoma and Therapeutic ImplicationsSemantic proximity Read ↗

Synergistic anti-tumor activity of EGFR inhibition and C/EBPβ antagonism in GBMSemantic proximity Read ↗

JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.